Latest fiscal year 2026 · computed deterministically from XBRL 10-K data · coverage 83%
In fiscal 2026, BIOTRICITY INC. reported revenue of $16M, up 16.0% year over year. Operating margin was 10.6% and net margin -15.0%, on a free-cash-flow margin of n/a with capital expenditure at n/a of revenue. Every figure is computed directly from BTCY's SEC XBRL 10-K filing — deterministic, with no estimates.
| Fiscal year | Revenue | Op margin | Net margin |
|---|---|---|---|
| FY2026 | $16M | 10.6% | -15.0% |
| FY2025 | $14M | -17.8% | -61.1% |
| FY2024 | $12M | -73.2% | -116.8% |
| FY2023 | $10M | -159.9% | -193.6% |
| FY2022 | $8M | -218.8% | -380.8% |
How does BTCY compare against its actual peer set?
A CompsDesk subscription covers unlimited benchmark packs on any covered company: up to 19 metrics (6 core guaranteed) × up to 5 fiscal years × up to 12 chosen peers, percentile placement, the subject's figures cited to their SEC tag, form and period with every company identified by its CIK, PDF-ready HTML + CSV, generated on demand.
Source: SEC EDGAR XBRL (10-K filings), latest filed values. "n/a" = not disclosed under mapped tags — never estimated. Informational benchmarking, not investment advice. © CompsDesk / Sam Arora.